Alyra Biotech is an early stage bio-pharmaceutical company with novel, patented, first-in-class, neuroimmune-modifying, intrauterine products to treat

neuroimmune conditions including pain in women.

These conditions include chronic pelvic pain, Irritable Bowel Syndrome, Painful Bladder Syndrome, Migraine, fatigue and endometriosis.

Alyra Biotech is guided by our close collaboration with consumers and end user research. Women are the centre of our innovation process.

______________________________________________

Immune activation within the uterus

Most of us have heard about the Gut-Brain Axis: the way our bowel health influences our wellbeing.

The uterus talks to our central nervous system too.... and it does so via the immune system.

Some women have excess activation of the immune system in their uterus and then suffer symptoms in the central nervous system like pain, fatigue, mood disorders and poor sleep.

Excess activation of the immune system also contributes to Irritable Bowel symptoms or Painful Bladder symptoms.

How does immune activation in the uterus impact the central nervous system?

This occurs via three mechanisms. Nerves that supply the uterus become sensitised. Immune cells within the uterus become activated and travel via the blood circulation to the central nervous system. And activated immune cells release chemicals called cytokines that make us feel unwell to the circulation.

Alyra Biotech is focussed on developing products that turn down the excess immune activation in the uterus to reduce these symptoms.

A truly innovative approach to conditions that affect women more than men and have previously been difficult to manage.

__________________________________________

Alyra Biotech Products

Alyra's patented products will suit continued use over a woman's reproductive lifetime.

They will provide a productivity dividend for women, society and health services.

Pain prevention will reduce the need for opioid medications.

Product development is de-risked by using drugs with known efficacy and long-term safety data in humans.

Targeted intrauterine release allows low dose, sustained drug release, with reduced systemic side effects.

We add an immune-inhibitor to an intrauterine device.

______________________________________________

A Next Phase in Contraception

By combining intrauterine delivery of immune inhibitors with an intrauterine device, Alyra Biotech brings new benefits,

and a reduction of adverse effects to trusted contraceptive methods.

Alyra Biotech's products offer a Next Phase in Contraception with strong appeal for today's young women.